R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories

Del
The RIDA®UNITY system from R-Biopharm for fully automated real-time PCR / Editorial use of this picture is free of charge. Please quote the source: "obs/R-Biopharm AG
The RIDA®UNITY system from R-Biopharm for fully automated real-time PCR / Editorial use of this picture is free of charge. Please quote the source: "obs/R-Biopharm AG

Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Biopharm AG announced today that it has received the CE mark and will begin selling the new, fully automated RIDA®UNITY system for molecular detection of infectious diseases throughout Europe.

"With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics," stated Christian Dreher, CEO of R-Biopharm. "We are very happy to make this system solution available to all molecular biology laboratories throughout Europe."

Unique combination of different tools

The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow – nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the results run fully automatically without user intervention. The ready-to-use RIDA®UNITY reagents significantly reduce the preparation times in the laboratory. The RIDA®UNITY Universal Extraction Kit allows the universal extraction of nucleic acids from both gastrointestinal and respiratory patient samples in a common workflow and was specifically developed and optimized by R-Biopharm. Up to six different RIDA®UNITY PCR assays can now be individually combined and processed.

The software especially developed for the RIDA®UNITY system supports the user with its simple and intuitive operation – from loading the required consumables and positioning the PCR reagents on the deck up to evaluating the final results. The RIDA®UNITY system supports molecular diagnostic laboratories with its flexibility in dealing with quickly changing requirements and thus noticeably facilitates everyday work in the laboratory.

"Today we can finally present the result of an incredible effort of diverse teams and many colleagues both from internal as well as external sources," says Dr. Lena Kastl, Vice President Clinical Diagnostics at R-Biopharm. "R-Biopharm's many years of product development and manufacturing expertise and the productive cooperation with various partners made the roll-out of this new molecular diagnostic platform possible. Thanks to its efficient, intuitive and universal application options, RIDA®UNITY will significantly support and improve workflow and capacities in the laboratories in the future.”

The RIDA®UNITY System, the RIDA®UNITY Universal Extraction Kit and the RIDA®UNITY Bacterial Stool Panel are now available for sale throughout Europe. Further assays for gastrointestinal and respiratory pathogens will follow in the coming months.

Kontakter

Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/contact/
https://r-biopharm.com/news-press/download-gallery/

R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Germany
Phone: +49 61 51 - 81 02-538
Email: s.feiler@r-biopharm.de

Billeder

The RIDA®UNITY system from R-Biopharm for fully automated real-time PCR / Editorial use of this picture is free of charge. Please quote the source: "obs/R-Biopharm AG
The RIDA®UNITY system from R-Biopharm for fully automated real-time PCR / Editorial use of this picture is free of charge. Please quote the source: "obs/R-Biopharm AG
Download

Information om R-Biopharm AG

R-Biopharm AG



Følg pressemeddelelser fra R-Biopharm AG

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra R-Biopharm AG

R-Biopharm announces test to detect monkeypox virus1.6.2022 13:27:17 CEST | Press release

Test for research purposes available soon R-Biopharm AG, a leading and globally operating biotechnology company based in Germany, will soon launch a test for the detection of monkeypox virus. The real-time PCR test, developed for research purposes (RUO), shall contribute to track and control the epidemiological spread of the virus. The product is expected to be available in approximately two to three weeks under the name RIDA®GENE Monkeypox Virus RUO (part number PG4915RUO). Like the test for the detection of the SARS-CoV-2 virus, which was the first to be launched by a German company for research purposes in February 2020 and was officially approved for the diagnosis of SARS-CoV-2 in the fall of 2020 with the CE mark, the real-time PCR test for the detection of monkeypox virus will also be usable on all common real-time PCR instruments. The uniform RIDA®GENE design also allows users to run this test together with other RIDA®GENE products. "R-Biopharm cares about the common good," says

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation7.12.2021 13:35:22 CET | Press release

R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (“CTDA”). R-Biopharm will now work to resume the sale of the product in the UK. RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus. Only validated products, or produc